With production GMP approved, Mithra's Myring contraceptive is well on schedule to storm the markets within less than a year.

To also serve geographies where BRAF testing is not reimbursed, Biocartis launches a new NRAS test next to their combined NRAS-BRAF assay.

With its Nasdaq debut, argenx raises $100 million, a significantly greater amount than the $60 million previously planned.

The first nanobody from the Ablynx-Merck collaboration reaches clinical development, triggering a €15m milestone payment to Ablynx.

While C-Cure had failed an essential phase 3 clinical trial in June last year, the trial identified a subgroup of patients where the drug was effective nonetheless. Based on this fact, C-Cure now receives Fast Track designation from the US drug policy maker.

Biocartis has revealed its pick for its vacant top function.